Accéder au contenu
Merck

Regional activation of the cancer genome by long-range epigenetic remodeling.

Cancer cell (2012-12-19)
Saul A Bert, Mark D Robinson, Dario Strbenac, Aaron L Statham, Jenny Z Song, Toby Hulf, Robert L Sutherland, Marcel W Coolen, Clare Stirzaker, Susan J Clark
RÉSUMÉ

Epigenetic gene deregulation in cancer commonly occurs through chromatin repression and promoter hypermethylation of tumor-associated genes. However, the mechanism underpinning epigenetic-based gene activation in carcinogenesis is still poorly understood. Here, we identify a mechanism of domain gene deregulation through coordinated long-range epigenetic activation (LREA) of regions that typically span 1 Mb and harbor key oncogenes, microRNAs, and cancer biomarker genes. Gene promoters within LREA domains are characterized by a gain of active chromatin marks and a loss of repressive marks. Notably, although promoter hypomethylation is uncommon, we show that extensive DNA hypermethylation of CpG islands or "CpG-island borders" is strongly related to cancer-specific gene activation or differential promoter usage. These findings have wide ramifications for cancer diagnosis, progression, and epigenetic-based gene therapies.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
Anticorps anti-triméthyl-histone H3 (Lys27), Upstate®, from rabbit
Sigma-Aldrich
Anticorps anti-acétyl-histone H3, from rabbit